Difference between revisions of "Rectal cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 1: Line 1:
−
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''
+
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''  
  
−
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].
+
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].
  
−
'''Please be aware that some regimens listed here are protocols for colon cancer, not rectal cancer. We have tried to only include rectal cancer protocols when they are available.'''
+
'''Please be aware that there are overlaps for protocols used in the treatment of colon and rectal cancer. We have tried to only include rectal cancer-specific protocols here, with links to the [[colon cancer]] page for non-specific colorectal cancer protocols.'''
  
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
−
|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
+
|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
−
<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
+
<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
Line 37: Line 37:
 
|-
 
|-
 
|}
 
|}
−
 
+
====Chemoradiotherapy====
−
*[[Capecitabine (Xeloda)]] 825 mg/m2 PO BID (1650 mg/m2/day) on days 1 to 38
+
*[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> PO BID (1650 mg/m<sup>2</sup>/day) on days 1 to 38
 
*Concurrent radiation therapy, 50.4 Gy total
 
*Concurrent radiation therapy, 50.4 Gy total
  
Line 89: Line 89:
 
|-
 
|-
 
|}
 
|}
−
 
+
====Chemoradiotherapy====
−
*[[Fluorouracil (5-FU)]] 1000 mg/m2/day IV continuous infusion on days 1 to 5, 29 to 33
+
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 5, 29 to 33
 
*Concurrent radiation therapy, 50.4 Gy total
 
*Concurrent radiation therapy, 50.4 Gy total
  
Line 98: Line 98:
  
 
===References===
 
===References===
−
# Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40. [http://www.nejm.org/doi/full/10.1056/NEJMoa040694 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/15496622 PubMed]
+
# Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40. [http://www.nejm.org/doi/full/10.1056/NEJMoa040694 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/15496622 PubMed]
 
## '''Update:''' Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012 Jun 1;30(16):1926-33. Epub 2012 Apr 23. [http://jco.ascopubs.org/content/30/16/1926.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22529255 PubMed]
 
## '''Update:''' Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012 Jun 1;30(16):1926-33. Epub 2012 Apr 23. [http://jco.ascopubs.org/content/30/16/1926.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22529255 PubMed]
 
# Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 12. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970116-X/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22503032 PubMed]
 
# Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 12. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970116-X/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22503032 PubMed]
Line 127: Line 127:
 
|-
 
|-
 
|}
 
|}
−
 
+
====Chemoradiotherapy====
−
*[[Fluorouracil (5-FU)]] 250 mg/m2/day IV continuous infusion on days 1 to 14, 22 to 35
+
*[[Fluorouracil (5-FU)]] 250 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 14, 22 to 35
−
*[[Oxaliplatin (Eloxatin)]] 50 mg/m2 IV once per day on days 1, 8, 22, 29
+
*[[Oxaliplatin (Eloxatin)]] 50 mg/m<sup>2</sup> IV once per day on days 1, 8, 22, 29
 
*Concurrent radiation therapy, 50.4 Gy total
 
*Concurrent radiation therapy, 50.4 Gy total
  
Line 164: Line 164:
  
 
''Treatment preceded by [[#Capecitabine_.26_RT|neoadjuvant capecitabine & RT]] and surgery.''
 
''Treatment preceded by [[#Capecitabine_.26_RT|neoadjuvant capecitabine & RT]] and surgery.''
 +
====Chemotherapy====
 +
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO BID (2500 mg/m<sup>2</sup>/day) on days 1 to 14
  
−
*[[Capecitabine (Xeloda)]] 1250 mg/m2 PO BID (2500 mg/m2/day) on days 1 to 14
+
'''21-day cycle for 5 cycles'''
−
 
 
−
'''21-day cycle x 5 cycles'''
 
  
 
===References===
 
===References===
Line 224: Line 224:
  
 
''Treatment preceded by [[#Fluorouracil_.26_RT|neoadjuvant fluorouracil & RT]] and surgery.''
 
''Treatment preceded by [[#Fluorouracil_.26_RT|neoadjuvant fluorouracil & RT]] and surgery.''
 +
====Chemotherapy====
 +
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
  
−
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV bolus once per day on days 1 to 5
+
'''28-day cycle for 4 cycles'''
−
 
 
−
'''28-day cycle x 4 cycles'''
 
  
 
===Regimen #2 {{#subobject:38a90a|Variant=1}}===
 
===Regimen #2 {{#subobject:38a90a|Variant=1}}===
Line 247: Line 247:
  
 
''Treatment preceded by [[#Fluorouracil_.26_RT|neoadjuvant fluorouracil & RT]] and surgery.''
 
''Treatment preceded by [[#Fluorouracil_.26_RT|neoadjuvant fluorouracil & RT]] and surgery.''
−
 
+
====Chemotherapy====
−
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV bolus once per day on days 1 to 5, 29
+
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5, 29
  
 
'''4 cycles (length not specified)'''
 
'''4 cycles (length not specified)'''
Line 280: Line 280:
  
 
''Treatment preceded by fluoropyrimidine-based chemoradiation and total mesorectal excision.''
 
''Treatment preceded by fluoropyrimidine-based chemoradiation and total mesorectal excision.''
 +
====Chemotherapy====
 +
*[[Fluorouracil (5-FU)]] 380 mg/m<sup>2</sup> IV once per day on days 1 to 5
 +
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV once per day on days 1 to 5
  
−
*[[Fluorouracil (5-FU)]] 380 mg/m2 IV once per day on days 1 to 5
+
'''28-day cycle for 4 cycles'''
−
*[[Folinic acid (Leucovorin)]] 20 mg/m2 IV once per day on days 1 to 5
 
−
 
 
−
'''28-day cycle x 4 cycles'''
 
  
 
===References===
 
===References===
Line 314: Line 314:
  
 
''Treatment preceded by fluoropyrimidine-based chemoradiation and total mesorectal excision.''
 
''Treatment preceded by fluoropyrimidine-based chemoradiation and total mesorectal excision.''
 +
====Chemotherapy====
 +
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus on day 1, then 1200 mg/m<sup>2</sup>/day IV continuous infusion over 46 hours (total dose: 2800 mg/m<sup>2</sup>)
 +
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV once on day 1
 +
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1
  
−
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day IV continuous infusion over 46 hours (total dose 2800 mg/m2)
+
'''14-day cycle for 8 cycles'''
−
*[[Folinic acid (Leucovorin)]] 200 mg/m2 IV once on day 1
 
−
*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV once on day 1
 
−
 
 
−
'''14-day cycle x 8 cycles'''
 
  
 
===Regimen #2 {{#subobject:f3300f|Variant=1}}===
 
===Regimen #2 {{#subobject:f3300f|Variant=1}}===
Line 339: Line 339:
  
 
''Treatment preceded by [[#Fluorouracil.2C_Oxaliplatin.2C_RT|neoadjuvant fluorouracil, oxaliplatin, RT]] and surgery. Note: it is unclear from the abstract whether the intent is for 8 cycles (16 doses of oxaliplatin) or 8 doses of oxaliplatin.''
 
''Treatment preceded by [[#Fluorouracil.2C_Oxaliplatin.2C_RT|neoadjuvant fluorouracil, oxaliplatin, RT]] and surgery. Note: it is unclear from the abstract whether the intent is for 8 cycles (16 doses of oxaliplatin) or 8 doses of oxaliplatin.''
−
 
+
====Chemotherapy====
−
*[[Fluorouracil (5-FU)]] 2400 mg/m2 IV continuous infusion over 48 hours twice per cycle on days 1 & 2, 15 & 16
+
*[[Fluorouracil (5-FU)]] 2400 mg/m<sup>2</sup> IV continuous infusion over 48 hours twice per cycle on days 1 & 2, 15 & 16
−
*[[Folinic acid (Leucovorin)]] 400 mg/m2 IV once per day on days 1 & 15
+
*[[Folinic acid (Leucovorin)]] 400 mg/m<sup>2</sup> IV once per day on days 1 & 15
−
*[[Oxaliplatin (Eloxatin)]] 100 mg/m2 IV once per day on days 1 & 15
+
*[[Oxaliplatin (Eloxatin)]] 100 mg/m<sup>2</sup> IV once per day on days 1 & 15
  
 
'''8 cycles'''
 
'''8 cycles'''
Line 376: Line 376:
 
|}
 
|}
  
−
Prior to chemoradiation:
+
====Chemotherapy, part 1====
−
*[[Capecitabine (Xeloda)]] 1250 mg/m2 PO BID (2500 mg/m2/day) on days 1 to 14
+
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO BID (2500 mg/m<sup>2</sup>/day) on days 1 to 14
  
−
'''21-day cycle x 2 cycles, followed by:'''
+
'''21-day cycle for 2 cycles, followed by:'''
  
−
====Chemoradiation====
+
====Chemoradiotherapy====
−
*[[Capecitabine (Xeloda)]] 825 mg/m2 PO BID (1650 mg/m2/day) on days 1 to 38
+
*[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> PO BID (1650 mg/m<sup>2</sup>/day) on days 1 to 38
 
*Concurrent radiation therapy, 50.4 Gy total
 
*Concurrent radiation therapy, 50.4 Gy total
  
 
'''Followed by:'''
 
'''Followed by:'''
−
*[[Capecitabine (Xeloda)]] 1250 mg/m2 PO BID (2500 mg/m2/day) on days 1 to 14
 
  
−
'''21-day cycle x 3 cycles'''
+
====Chemotherapy, part 2====
 +
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO BID (2500 mg/m<sup>2</sup>/day) on days 1 to 14
 +
 
 +
'''21-day cycle for 3 cycles'''
  
 
===References===
 
===References===
Line 400: Line 402:
 
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
 
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
  
−
===Regimen #1, Bolus 5-FU (500 mg/m2) -> 5-FU & RT -> Bolus 5-FU (450 mg/m2) {{#subobject:d06581|Variant=1}}===
+
===Regimen #1, Bolus 5-FU (500 mg/m<sup>2</sup>) -> 5-FU & RT -> Bolus 5-FU (450 mg/m<sup>2</sup>) {{#subobject:d06581|Variant=1}}===
 
{| border="1" style="text-align:center;" !align="left"  
 
{| border="1" style="text-align:center;" !align="left"  
 
|'''Study'''
 
|'''Study'''
Line 416: Line 418:
 
|-
 
|-
 
|}
 
|}
 +
====Chemotherapy, part 1====
 +
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
  
−
Prior to chemoradiation:
+
'''28-day cycle for 2 cycles, followed immediately by:'''
−
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV bolus once per day on days 1 to 5
 
  
−
'''28-day cycle x 2 cycles, followed immediately by:'''
+
====Chemoradiotherapy====
−
 
+
*[[Fluorouracil (5-FU)]] 225 mg/m<sup>2</sup>/day IV continuous infusion while radiation is being given
−
====Chemoradiation====
 
−
*[[Fluorouracil (5-FU)]] 225 mg/m2/day IV continuous infusion while radiation is being given
 
 
*Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided
 
*Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided
  
−
'''One course, followed 28 days after completion of chemoradiation by:'''
+
'''One course, followed 28 days later by:'''
  
−
*[[Fluorouracil (5-FU)]] 450 mg/m2 IV bolus once per day on days 1 to 5
+
====Chemotherapy, part 2====
 +
*[[Fluorouracil (5-FU)]] 450 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
  
−
'''28-day cycle x 2 cycles'''
+
'''28-day cycle for 2 cycles'''
  
−
===Regimen #2, Bolus 5-FU (500 mg/m2) -> 5-FU & RT -> Bolus 5-FU (500 mg/m2) {{#subobject:23bcde|Variant=1}}===
+
===Regimen #2, Bolus 5-FU (500 mg/m<sup>2</sup>) -> 5-FU & RT -> Bolus 5-FU (500 mg/m<sup>2</sup>) {{#subobject:23bcde|Variant=1}}===
 
{| border="1" style="text-align:center;" !align="left"  
 
{| border="1" style="text-align:center;" !align="left"  
 
|'''Study'''
 
|'''Study'''
Line 448: Line 450:
 
|-
 
|-
 
|}
 
|}
 +
====Chemotherapy, part 1====
 +
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
  
−
Prior to chemoradiation:
+
'''28-day cycle for 2 cycles, followed by:'''
−
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV bolus once per day on days 1 to 5
 
  
−
'''28-day cycle x 2 cycles, followed by:'''
+
====Chemoradiotherapy====
−
 
+
*[[Fluorouracil (5-FU)]] 225 mg/m<sup>2</sup>/day IV continuous infusion while radiation is being given
−
====Chemoradiation====
 
−
*[[Fluorouracil (5-FU)]] 225 mg/m2/day IV continuous infusion while radiation is being given
 
 
*Concurrent radiation therapy, 50.4 Gy total
 
*Concurrent radiation therapy, 50.4 Gy total
  
 
'''Followed by:'''
 
'''Followed by:'''
  
−
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV bolus once per day on days 1 to 5
+
====Chemotherapy, part 2====
 +
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
  
−
'''28-day cycle x 2 cycles'''
+
'''28-day cycle for 2 cycles'''
  
 
===Regimen #3, Continuous 5-FU -> 5-FU & RT -> Continuous 5-FU {{#subobject:da8c0d|Variant=1}}===
 
===Regimen #3, Continuous 5-FU -> 5-FU & RT -> Continuous 5-FU {{#subobject:da8c0d|Variant=1}}===
Line 481: Line 483:
 
|}
 
|}
  
−
Prior to chemoradiation:
+
====Chemotherapy, part 1====
−
*[[Fluorouracil (5-FU)]] 300 mg/m2/day IV continuous infusion on days 1 to 42
+
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 42
  
−
'''8-week course''' (2 weeks off of chemotherapy prior to chemoradiation)
+
'''8-week course, followed in 2 weeks by:'''
  
−
====Chemoradiation====
+
====Chemoradiotherapy====
−
*[[Fluorouracil (5-FU)]] 225 mg/m2/day IV continuous infusion while radiation is being given
+
*[[Fluorouracil (5-FU)]] 225 mg/m<sup>2</sup>/day IV continuous infusion while radiation is being given
 
*Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided
 
*Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided
  
 
'''Followed in 28 days by:'''
 
'''Followed in 28 days by:'''
−
*[[Fluorouracil (5-FU)]] 300 mg/m2/day IV continuous infusion on days 1 to 56
+
 
 +
====Chemotherapy, part 2====
 +
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 56
  
 
'''56-day course'''
 
'''56-day course'''
Line 511: Line 515:
 
|-
 
|-
 
|}
 
|}
 +
====Chemotherapy, part 1====
 +
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
  
−
Prior to chemoradiation:
+
'''28-day cycle for 2 cycles, followed by:'''
−
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV bolus once per day on days 1 to 5
 
  
−
'''28-day cycle x 2 cycles, followed by:'''
+
====Chemoradiotherapy====
−
 
+
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV bolus 3 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
−
====Chemoradiation====
 
−
*[[Fluorouracil (5-FU)]] 500 mg/m2 IV bolus 3 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
 
 
*Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided
 
*Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided
  
 
'''Followed in 28 days by:'''
 
'''Followed in 28 days by:'''
−
*[[Fluorouracil (5-FU)]] 450 mg/m2 IV bolus once per day on days 1 to 5
 
  
−
'''28-day cycle x 2 cycles'''
+
====Chemotherapy, part 2====
 +
*[[Fluorouracil (5-FU)]] 450 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
 +
 
 +
'''28-day cycle for 2 cycles'''
  
 
===Regimen #5 {{#subobject:4b7461|Variant=1}}===
 
===Regimen #5 {{#subobject:4b7461|Variant=1}}===
−
Level of Evidence:
 
−
<span
 
−
style="background:#EEEE00;
 
−
padding:3px 6px 3px 6px;
 
−
border-color:black;
 
−
border-width:2px;
 
−
border-style:solid;">Non-randomized</span>
 
  
−
''Note: The O'Connell et al. 1994 reference cited by the NCCN, Rectal Cancer version 3.2012, contains a different regimen than what is listed by the NCCN. No primary reference could be found for this exact regimen as listed by the NCCN.''
+
''Note: The O'Connell et al. 1994 reference cited by the NCCN, Rectal Cancer version 3.2012, contains a different regimen than what is listed by the NCCN. No primary reference could be found for this exact regimen as listed by the NCCN.''
−
*[[Fluorouracil (5-FU)]] 225 mg/m2/day IV continuous infusion either 5 or 7 days per week during radiation therapy
+
 
 +
*[[Fluorouracil (5-FU)]] 225 mg/m<sup>2</sup>/day IV continuous infusion either 5 or 7 days per week during radiation therapy
  
 
===References===
 
===References===
Line 543: Line 542:
 
## '''Update:''' Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol. 2002 Apr 1;20(7):1744-50. [http://jco.ascopubs.org/content/20/7/1744.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11919230 PubMed] content property of [http://hemonc.org HemOnc.org]
 
## '''Update:''' Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol. 2002 Apr 1;20(7):1744-50. [http://jco.ascopubs.org/content/20/7/1744.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11919230 PubMed] content property of [http://hemonc.org HemOnc.org]
 
# Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB 3rd, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS Jr, Leichman CG, Macdonald JS. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006 Aug 1;24(22):3542-7. [http://jco.ascopubs.org/content/24/22/3542.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16877719 PubMed]
 
# Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB 3rd, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS Jr, Leichman CG, Macdonald JS. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006 Aug 1;24(22):3542-7. [http://jco.ascopubs.org/content/24/22/3542.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16877719 PubMed]
−
# Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Apr 12. [Epub ahead of print] [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970116-X/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22503032 PubMed]
+
# Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 13. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970116-X/fulltext link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22503032 PubMed]
  
 
==5-FU & Leucovorin -> 5-FU, Leucovorin, RT -> 5-FU & Leucovorin {{#subobject:e9de02|Regimen=1}}==
 
==5-FU & Leucovorin -> 5-FU, Leucovorin, RT -> 5-FU & Leucovorin {{#subobject:e9de02|Regimen=1}}==
Line 550: Line 549:
 
|[[#toc|back to top]]
 
|[[#toc|back to top]]
 
|}
 
|}
 +
RT: '''<u>R</u>'''adiation '''<u>T</u>'''herapy
 
===Regimen {{#subobject:cd06ac|Variant=1}}===
 
===Regimen {{#subobject:cd06ac|Variant=1}}===
 
{| border="1" style="text-align:center;" !align="left"  
 
{| border="1" style="text-align:center;" !align="left"  
Line 566: Line 566:
 
|-
 
|-
 
|}
 
|}
 +
====Chemotherapy, part 1====
 +
*[[Fluorouracil (5-FU)]] 425 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5, '''given after Folinic acid (Leucovorin)'''
 +
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5, '''given before Fluorouracil (5-FU)'''
  
−
Prior to chemoradiation:
+
'''28-day cycle for 2 cycles, followed by:'''
−
*[[Fluorouracil (5-FU)]] 425 mg/m2 IV bolus once per day on days 1 to 5, '''given after Folinic acid (Leucovorin)'''
 
−
*[[Folinic acid (Leucovorin)]] 20 mg/m2 IV bolus once per day on days 1 to 5, '''given before Fluorouracil (5-FU)'''
 
  
−
'''28-day cycle x 2 cycles, followed by:'''
+
====Chemoradiotherapy====
−
 
+
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus 4 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
−
====Chemoradiation====
+
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus 4 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
−
*[[Fluorouracil (5-FU)]] 400 mg/m2 IV bolus 4 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
 
−
*[[Folinic acid (Leucovorin)]] 20 mg/m2 IV bolus 4 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
 
 
*Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided
 
*Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided
  
 
'''Followed in 28 days by:'''
 
'''Followed in 28 days by:'''
−
*[[Fluorouracil (5-FU)]] 380 mg/m2 IV bolus once per day on days 1 to 5
 
−
*[[Folinic acid (Leucovorin)]] 20 mg/m2 IV bolus once per day on days 1 to 5
 
  
−
'''28-day cycle x 2 cycles'''
+
====Chemotherapy, part 2====
 +
*[[Fluorouracil (5-FU)]] 380 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
 +
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
 +
 
 +
'''28-day cycle for 2 cycles'''
  
 
===References===
 
===References===
Line 612: Line 613:
  
 
''Two levamisole combinations were evaluated and neither were superior; here for reference purposes only.''
 
''Two levamisole combinations were evaluated and neither were superior; here for reference purposes only.''
−
 
+
====Chemotherapy====
 
*[[Folinic acid (Leucovorin)]]
 
*[[Folinic acid (Leucovorin)]]
 
*[[Fluorouracil (5-FU)]]
 
*[[Fluorouracil (5-FU)]]
Line 622: Line 623:
  
 
=Advanced or metastatic disease=
 
=Advanced or metastatic disease=
−
See [[Colon cancer#Advanced_or_metastatic_disease|Colon cancer - Advanced or metastatic disease]]. The regimens listed by the NCCN, Rectal Cancer version 3.2012, are identical to the list for Colon Cancer version 2.2012, with the same references.
+
See [[Colon cancer#Advanced_or_metastatic_disease|Colon cancer - Advanced or metastatic disease]]. The regimens listed by the NCCN, Rectal Cancer version 3.2012, are identical to the list for Colon Cancer version 2.2012, with the same references.
  
 
[[Category:Chemotherapy regimens]]
 
[[Category:Chemotherapy regimens]]
 
[[Category:Solid oncology regimens]]
 
[[Category:Solid oncology regimens]]
 
[[Category:Gastrointestinal (GI) oncology regimens]]
 
[[Category:Gastrointestinal (GI) oncology regimens]]

Revision as of 17:25, 20 August 2016

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Please be aware that there are overlaps for protocols used in the treatment of colon and rectal cancer. We have tried to only include rectal cancer-specific protocols here, with links to the colon cancer page for non-specific colorectal cancer protocols.

22 regimens on this page
48 variants on this page


Neoadjuvant chemoradiation

Capecitabine & RT

back to top

RT: Radiation Therapy

Regimen

Study Evidence Comparator
Hofheinz et al. 2012 Phase III 5-FU & RT

Chemoradiotherapy

  • Capecitabine (Xeloda) 825 mg/m2 PO BID (1650 mg/m2/day) on days 1 to 38
  • Concurrent radiation therapy, 50.4 Gy total

One course

After surgery, patients proceeded to receive adjuvant capecitabine.

References

  1. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 12. link to original article contains verified protocol PubMed

Fluorouracil & RT

back to top

RT: Radiation Therapy

Regimen

Study Evidence Comparator
Sauer et al. 2004 (CAO/ARO/AIO-94) Phase III Adjuvant 5-FU & RT
Hofheinz et al. 2012 Phase III Capecitabine & RT
Rödel et al. 2012 (CAO/ARO/AIO-04) Phase III Fluorouracil, Oxaliplatin, RT

Chemoradiotherapy

  • Fluorouracil (5-FU) 1000 mg/m2/day IV continuous infusion on days 1 to 5, 29 to 33
  • Concurrent radiation therapy, 50.4 Gy total

One course

After surgery, patients proceeded to receive adjuvant fluorouracil.

References

  1. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004 Oct 21;351(17):1731-40. link to original article PubMed
    1. Update: Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012 Jun 1;30(16):1926-33. Epub 2012 Apr 23. link to original article PubMed
  2. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 12. link to original article contains verified protocol PubMed
  3. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87. Epub 2012 May 23. link to original article contains protocol PubMed
    1. Update: Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. Epub 2015 Jul 15. link to original article PubMed

Fluorouracil, Oxaliplatin, RT

back to top

RT: Radiation Therapy

Regimen

Study Evidence Comparator
Rödel et al. 2012 (CAO/ARO/AIO-04) Phase III Fluorouracil & RT

Chemoradiotherapy

One course

After surgery, patients proceeded to receive adjuvant FOLFOX.

References

  1. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87. Epub 2012 May 23. link to original article contains protocol PubMed
    1. Update: Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. Epub 2015 Jul 15. link to original article PubMed

Adjuvant chemotherapy

Capecitabine (Xeloda)

back to top

Regimen

Study Evidence Comparator
Hofheinz et al. 2012 Phase III Fluorouracil

Treatment preceded by neoadjuvant capecitabine & RT and surgery.

Chemotherapy

21-day cycle for 5 cycles

References

  1. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 12. link to original article contains verified protocol PubMed

CapeOx (XELOX)

back to top

CapeOX: Capecitabine, OXaliplatin
XELOX: XELoda (Capecitabine), OXaliplatin

Regimen

See CapeOx for adjuvant treatment of colon cancer.

References

  1. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. link to original article contains verified protocol PubMed
    1. Update: Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011 Apr 10;29(11):1465-71. Epub 2011 Mar 7. link to original article PubMed
  2. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011 Apr 10;29(11):1465-71. Epub 2011 Mar 7. link to original article contains verified protocol PubMed

FLOX

back to top

FLOX: Fluorouracil, Leucovorin, OXaliplatin

Regimen

See FLOX for adjuvant treatment of colon cancer.

References

  1. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30. link to original article contains verified protocol PubMed

Fluorouracil (5-FU)

back to top

Regimen #1

Study Evidence Comparator
Hofheinz et al. 2012 Phase III Capecitabine

Treatment preceded by neoadjuvant fluorouracil & RT and surgery.

Chemotherapy

28-day cycle for 4 cycles

Regimen #2

Study Evidence Comparator
Rödel et al. 2012 (CAO/ARO/AIO-04) Phase III FOLFOX

Treatment preceded by neoadjuvant fluorouracil & RT and surgery.

Chemotherapy

4 cycles (length not specified)

References

  1. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 12. link to original article contains verified protocol PubMed
  2. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87. Epub 2012 May 23. link to original article contains protocol PubMed
    1. Update: Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. Epub 2015 Jul 15. link to original article PubMed

Fluorouracil & Folinic acid

back to top

Regimen

Study Evidence Comparator
Hong et al. 2014 (ADORE) Randomized Phase II FOLFOX

Treatment preceded by fluoropyrimidine-based chemoradiation and total mesorectal excision.

Chemotherapy

28-day cycle for 4 cycles

References

  1. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014 Oct;15(11):1245-53. Epub 2014 Sep 4. link to original article contains protocol PubMed

FOLFOX

back to top

FOLFOX: FOLinic acid, Fluorouracil, OXaliplatin

Regimen #1

Study Evidence Comparator
Hong et al. 2014 (ADORE) Randomized Phase II Fluorouracil & 5-FU

Treatment preceded by fluoropyrimidine-based chemoradiation and total mesorectal excision.

Chemotherapy

14-day cycle for 8 cycles

Regimen #2

Study Evidence Comparator
Rödel et al. 2012 (CAO/ARO/AIO-04) Phase III Fluorouracil

Treatment preceded by neoadjuvant fluorouracil, oxaliplatin, RT and surgery. Note: it is unclear from the abstract whether the intent is for 8 cycles (16 doses of oxaliplatin) or 8 doses of oxaliplatin.

Chemotherapy

8 cycles

References

  1. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014 Oct;15(11):1245-53. Epub 2014 Sep 4. link to original article contains protocol PubMed
  2. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87. Epub 2012 May 23. link to original article contains protocol PubMed
    1. Update: Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. Epub 2015 Jul 15. link to original article PubMed

Adjuvant chemoradiation

Capecitabine -> Capecitabine & RT -> Capecitabine

back to top

RT: Radiation Therapy

Regimen

Study Evidence Comparator
Hofheinz et al. 2012 Phase III 5-FU -> 5-FU & RT -> 5-FU

Chemotherapy, part 1

21-day cycle for 2 cycles, followed by:

Chemoradiotherapy

  • Capecitabine (Xeloda) 825 mg/m2 PO BID (1650 mg/m2/day) on days 1 to 38
  • Concurrent radiation therapy, 50.4 Gy total

Followed by:

Chemotherapy, part 2

21-day cycle for 3 cycles

References

  1. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 12. link to original article contains verified protocol PubMed

Fluorouracil -> Fluorouracil & RT -> Fluorouracil

back to top

RT: Radiation Therapy

Regimen #1, Bolus 5-FU (500 mg/m2) -> 5-FU & RT -> Bolus 5-FU (450 mg/m2)

Study Evidence Comparator
Smalley et al. 2006 (GI INT 0144) Phase III Bolus 5-FU -> RT -> Bolus 5-FU
Continuous 5-FU -> 5-FU & RT -> Continuous 5-FU

Chemotherapy, part 1

28-day cycle for 2 cycles, followed immediately by:

Chemoradiotherapy

  • Fluorouracil (5-FU) 225 mg/m2/day IV continuous infusion while radiation is being given
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided

One course, followed 28 days later by:

Chemotherapy, part 2

28-day cycle for 2 cycles

Regimen #2, Bolus 5-FU (500 mg/m2) -> 5-FU & RT -> Bolus 5-FU (500 mg/m2)

Study Evidence Comparator
Hofheinz et al. 2012 Phase III Capecitabine -> Capecitabine & RT -> Capecitabine

Chemotherapy, part 1

28-day cycle for 2 cycles, followed by:

Chemoradiotherapy

  • Fluorouracil (5-FU) 225 mg/m2/day IV continuous infusion while radiation is being given
  • Concurrent radiation therapy, 50.4 Gy total

Followed by:

Chemotherapy, part 2

28-day cycle for 2 cycles

Regimen #3, Continuous 5-FU -> 5-FU & RT -> Continuous 5-FU

Study Evidence Comparator
Smalley et al. 2006 (GI INT 0144) Phase III Bolus 5-FU -> 5-FU & RT -> Bolus 5-FU
Bolus 5-FU -> RT -> Bolus 5-FU

Chemotherapy, part 1

8-week course, followed in 2 weeks by:

Chemoradiotherapy

  • Fluorouracil (5-FU) 225 mg/m2/day IV continuous infusion while radiation is being given
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided

Followed in 28 days by:

Chemotherapy, part 2

56-day course

Regimen #4

Study Evidence Comparator
Tepper et al. 1997 (GI INT 0114) Phase III 5-FU & Leucovorin -> 5-FU, Leucovorin, RT -> 5-FU & Leucovorin
Levamisole combination #1
Levamisole combination #2

Chemotherapy, part 1

28-day cycle for 2 cycles, followed by:

Chemoradiotherapy

  • Fluorouracil (5-FU) 500 mg/m2 IV bolus 3 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided

Followed in 28 days by:

Chemotherapy, part 2

28-day cycle for 2 cycles

Regimen #5

Note: The O'Connell et al. 1994 reference cited by the NCCN, Rectal Cancer version 3.2012, contains a different regimen than what is listed by the NCCN. No primary reference could be found for this exact regimen as listed by the NCCN.

  • Fluorouracil (5-FU) 225 mg/m2/day IV continuous infusion either 5 or 7 days per week during radiation therapy

References

  1. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994 Aug 25;331(8):502-7. link to original article PubMed
  2. Tepper JE, O'Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol. 1997 May;15(5):2030-9. link to original article contains verified protocol PubMed
    1. Update: Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol. 2002 Apr 1;20(7):1744-50. link to original article contains verified protocol PubMed content property of HemOnc.org
  3. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB 3rd, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS Jr, Leichman CG, Macdonald JS. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006 Aug 1;24(22):3542-7. link to original article contains verified protocol PubMed
  4. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012 Jun;13(6):579-88. Epub 2012 Apr 13. link to original article contains verified protocol PubMed

5-FU & Leucovorin -> 5-FU, Leucovorin, RT -> 5-FU & Leucovorin

back to top

RT: Radiation Therapy

Regimen

Study Evidence Comparator
Tepper et al. 1997 (GI INT 0114) Phase III 5-FU -> 5-FU & RT -> 5-FU
Levamisole combination #1
Levamisole combination #2

Chemotherapy, part 1

28-day cycle for 2 cycles, followed by:

Chemoradiotherapy

  • Fluorouracil (5-FU) 400 mg/m2 IV bolus 4 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
  • Folinic acid (Leucovorin) 20 mg/m2 IV bolus 4 days per week during weeks 1 & 5 of radiation, preferably within 2 hours after the day's radiation
  • Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions for an initial dose of 45 Gy, which is followed by a 1.8 Gy x 3 fraction (5.4 Gy total) boost to the tumor bed and adjacent lymph nodes, and then optionally a 1.8 Gy x 2 fraction (3.6 Gy total) boost to the tumor bed and a 2 cm margin if the small bowel could be avoided

Followed in 28 days by:

Chemotherapy, part 2

28-day cycle for 2 cycles

References

  1. Tepper JE, O'Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol. 1997 May;15(5):2030-9. link to original article contains verified protocol PubMed
    1. Update: Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol. 2002 Apr 1;20(7):1744-50. link to original article contains verified protocol PubMed

Fluorouracil, Folinic acid, Levamisole, RT

back to top

RT: Radiation Therapy

Regimen

Study Evidence Comparator
Tepper et al. 1997 (GI INT 0114) Phase III 5-FU -> 5-FU & RT -> 5-FU
5-FU & Leucovorin -> 5-FU, Leucovorin, RT -> 5-FU & Leucovorin

Two levamisole combinations were evaluated and neither were superior; here for reference purposes only.

Chemotherapy

References

  1. Tepper JE, O'Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol. 1997 May;15(5):2030-9. link to original article contains verified protocol PubMed
    1. Update: Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA, Mayer RJ. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol. 2002 Apr 1;20(7):1744-50. link to original article contains verified protocol PubMed

Advanced or metastatic disease

See Colon cancer - Advanced or metastatic disease. The regimens listed by the NCCN, Rectal Cancer version 3.2012, are identical to the list for Colon Cancer version 2.2012, with the same references.

Retrieved from "https://hemonc.org/w/index.php?title=Rectal_cancer&oldid=11502"